{"organizations": ["Novogen"], "uuid": "da6b87d8ce5f38d62c50c7589260a78f9b5717e3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "au.finance.yahoo.com", "main_image": "https://s.yimg.com/bt/api/res/1.2/6rik6AZwuPGCiADf_9dhPQ--/YXBwaWQ9eW5ld3M7cT03NTt3PTYwMA--/http://l.yimg.com/os/mit/media/m/social/images/social_default_logo-1481777.png", "site_section": "https://au.finance.yahoo.com/news/topic-top-stories/?format=rss", "section_title": "Australian Business & World Finance News - Yahoo!7 Finance", "url": "https://au.finance.yahoo.com/news/novogen-review-pre-clinical-programs-012144777.html", "country": "GB", "title": "Novogen to review pre-clinical programs", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "Novogen to review pre-clinical programs", "spam_score": 0.0, "site_type": "news", "published": "2015-07-30T04:21:00.000+03:00", "replies_count": 0, "uuid": "da6b87d8ce5f38d62c50c7589260a78f9b5717e3"}, "author": "", "url": "https://au.finance.yahoo.com/news/novogen-review-pre-clinical-programs-012144777.html", "ord_in_thread": 0, "title": "Novogen to review pre-clinical programs", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Print \nCancer drug developer Novogen is reviewing its research programs so it can focus its limited resources on those with the most potential. \nActing chief executive Iain Ross says Novogen is in solid shape, but it cannot realistically fully resource all its development programs through to market approval and launch. \n\"Accordingly I have initiated a company-wide review, and I am working closely with the board, management and company's scientific advisers to review immediately the pre-clinical programs in detail,\" Mr Ross said on Thursday. \n\"Whilst not wanting to pre-empt the outcome of the review I anticipate we may have to re-prioritise some of the programs.\" \nMr Ross said Novogen did not rule out securing partners to help fund and develop its research programs, but mergers and acquisitions were not among its plans. \nNovogen intends to provide a shareholder update on the review by September 1, 2015. \nIain Ross was last week appointed to run Novogen after former chief executive and founder Graham Kelly resigned to pursue his own research. \nMr Ross said he had started a search for a world-class chief executive officer. \nThe company will also recruit more staff, including a full-time chief medical officer. \nNovogen has two cancer drugs in development - Cantrixil and Anisina - that it aims to progress to clinical trials in 2016. \nA third dug, Trilexium, could be progressed to human trials in 2016/17. \nCantrixil is designed to be injected into the peritoneal cavity to fight cancer cells and cancer-initiating cells thought to be responsible for cancer recurrence after chemotherapy. \nAnisina is a small molecule that works to undermine the structural integrity of cancer cells, causing the cells to die. \nTrilexium affects the viability of cancer cells by increasing rates of cell death and reducing proliferation. \nNovogen is listed on the Australian share market and the NASDAQ index in the US. \nShares in Novogen were 0.5 cents higher at 20.5 cents at 1108 AEST. @y7finance on Twitter, become a fan on Facebook Building approvals tipped to fall AAP \nBuilding approvals are expected to have fallen in June after posting a strong surge the month before. Economists â€¦", "external_links": [], "published": "2015-07-30T04:21:00.000+03:00", "crawled": "2015-07-30T04:40:56.043+03:00", "highlightTitle": ""}